Whitehawk says PTK7 expression stays stable after standard care in EGFR wild-type NSCLC, supporting HWK-007 ADC targetability

• Whitehawk Therapeutics flagged new real-world analyses backing PTK7 as a durable ADC target in pretreated EGFR wild-type NSCLC.
• Results will be presented at the World Conference on Lung Cancer in Seoul on Sept. 14, 2026.
• PTK7 expression stayed broadly stable through standard therapies, supporting use of PTK7-directed treatment in later-line settings.
• Survival outcomes did not appear to differ by PTK7 expression, positioning PTK7 as a delivery marker rather than a prognostic signal.
• Findings support the development rationale for HWK-007, a PTK7-directed ADC in Phase 1 testing in EGFR wild-type NSCLC and gynecologic cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609132130PR_NEWS_USPR_____LA46059) on September 14, 2026, and is solely responsible for the information contained therein.